Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
17 EVENTS
Established our company at 67 Asahimachi, Kurume City, Fukuoka Prefecture (Capital: 10,000 thousand yen)
Initiated Phase I clinical trial for castration-resistant prostate cancer with ITK-1
Concluded an exclusive license agreement with Fujifilm Corporation regarding ITK-1
Initiated Phase III clinical trial for castration-resistant prostate cancer with ITK-1
Results of interim analysis of Phase III clinical trial for castration-resistant prostate cancer with ITK-1 indicate a high likelihood of achieving the main evaluation items in the final analysis, and the Effectiveness and Safety Evaluation Committee recommends continuing the trial as planned.
Started Phase I clinical trial in the US for melanoma (malignant melanoma) with GRN-1201
Listed on the Tokyo Stock Exchange Mothers Market
Established Kawasaki Drug Discovery Institute in the Tonemachi district, Kawasaki City, Kanagawa Prefecture
Initiated Phase II clinical trial in the US for non-small cell lung cancer using GRN-1201 in combination with immune checkpoint inhibitors
Changed company name to BrightPath Biotherapeutics Co., Ltd.
Participated in the iPS cell-derived regenerative NKT cell therapy development project by RIKEN, a National Research and Development Agency
Conducted key opening for Phase III clinical trial of ITK-1 in patients with castration-resistant prostate cancer
Discontinued development of ITK-1
Relocated head office to 3-25-22 Tonemachi, Kawasaki-ku, Kawasaki City, Kanagawa Prefecture
Initiated physician-led clinical trial of iPS-NKT cell therapy
Initiated physician-led clinical trial of HER2 CAR-T cell therapy (BP2301)
Announced early termination of Phase II clinical trial of GRN-1201 in the US
§07
News
82 ARTICLES
Publication of a paper on iPS cell-derived CAR-NKT cells
A co-authored paper with the RIKEN and Chiba University research groups on iPS cell-derived CAR-NKT cells targeting solid tumors, which Bright Path Bio is researching, was published in the "Journal for ImmunoTherapy of Cancer" on October 20, 2026. The paper discusses how HER2-targeted CAR-NKT cells exhibit multifaceted immune regulatory functions beyond direct tumor damage.
Publication of Paper on iPSC-derived CAR-NKT Cells
A co-authored paper with the Institute of Physical and Chemical Research and Chiba University, concerning iPSC-derived CAR-NKT cells targeting solid tumors, was published in the journal 'Journal for ImmunoTherapy of Cancer' on October 20, 2026. The paper reports that CAR-NKT cells targeting HER2 not only directly damage tumors but also exhibit multifaceted immune regulatory functions.
Announcement of Completion of Payment for the 21st Issue of Stock Options Allocated to Third Parties
Bright Path Bio Inc. reported that it has completed the payment for the 21st issuance of stock options (with exercise price adjustment clause) allocated to third parties. The number of shares issued was 345,000, with a total amount of 2,415,000 yen, and the payment of 1,952,915,000 yen was completed. The potential number of shares is 34,500,000, with an initial exercise price of 57 yen, which will be adjusted according to 97% of the closing price of the exchange.
Announcement of Completion of Payment for the 21st Issue of Stock Rights with Exercise Price Adjustment Clause
On October 5, 2026, we issued the 21st stock rights (with exercise price adjustment clause) through a third‑party allocation, and the payment of 2,415,000 yen was completed. The number of shares issued was 345,000, and the potential number of shares is 34,500,000 (100 shares per right). The exercise price was initially 57 yen, and from the trading day following the allocation date, it will be adjusted based on 97% of the closing price of the exchange.
Nikkei Bio Online Covers BrightPath Bio’s U.S. Clinical Trial Start
On September 28, 2026, Nikkei Bio Online published an article about the start of a U.S. clinical trial of BrightPath Bio’s allogeneic iPS cell-derived CAR-NKT therapy.
Nikkei Bio Online Covers BrightPath Bio’s U.S. Clinical Trial Start
On September 28, 2026, Nikkei Bio Online published an article about the start of a U.S. clinical trial of BrightPath Bio’s allogeneic iPS cell-derived CAR-NKT therapy.
Notice of BrightPath Publication (September 25, 2026)
BrightPath Bio Inc. is participating in the annual scientific conference of the International Myeloma Society (IMS2026).
Notice of BrightPath Newsletter Publication (September 25, 2026)
BrightPath Bio Inc. is participating in the annual scientific conference of the International Myeloma Society (IMS2026). The news has been published in the BrightPath Newsletter.
Research on iPS Cell-Derived BCMA CAR-NKT Therapy Presented
BrightPath Biotherapeutics presented preclinical research results on its iPS cell-derived BCMA CAR-NKT cell therapy (BP2202) and the design of its Phase I clinical trial at IMS 2026 on September 23, 2026.
Supplementary Video on 21st Stock Acquisition Rights Offering Published
BrightPath Biotherapeutics Co., Ltd. posted a supplementary explanatory video on September 24, 2026, concerning its issuance of the 21st stock acquisition rights with an exercise price adjustment clause.
§08
Public records
GOV
National Tax Agency basic information8290001050314
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
ブライトパス・バイオ株式会社
Trade name (kana)
ブライトパスバイオ
Name in English
Corporation type
301
Address
〒210-0821 神奈川県川崎市川崎区殿町3丁目25番22号
Postal code
2100821
Prefecture code
14
City code
131
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2019-07-23
Change date
2019-07-18
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2937666
METI gBizINFO8290001050314
Source: gBizINFO (Ministry of Economy, Trade and Industry)